GB Sciences Past Earnings Performance
Past criteria checks 0/6
GB Sciences has been growing earnings at an average annual rate of 50.2%, while the Pharmaceuticals industry saw earnings growing at 1% annually. Revenues have been declining at an average rate of 84.7% per year.
Key information
50.2%
Earnings growth rate
63.5%
EPS growth rate
| Pharmaceuticals Industry Growth | 6.0% |
| Revenue growth rate | -84.7% |
| Return on equity | n/a |
| Net Margin | n/a |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses BreakdownBeta
How GB Sciences makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 0 | -4 | 1 | 0 |
| 30 Sep 23 | 0 | -4 | 1 | 0 |
| 30 Jun 23 | 0 | -4 | 1 | 0 |
| 31 Mar 23 | 0 | -4 | 1 | 0 |
| 31 Dec 22 | 0 | -5 | 1 | 1 |
| 30 Sep 22 | 0 | 0 | 1 | 1 |
| 30 Jun 22 | 0 | 0 | 1 | 1 |
| 31 Mar 22 | 0 | 0 | 1 | 1 |
| 31 Dec 21 | 0 | 3 | 1 | 0 |
| 30 Sep 21 | 0 | -2 | 2 | 0 |
| 30 Jun 21 | 0 | -2 | 2 | 0 |
| 31 Mar 21 | 0 | -3 | 2 | 0 |
| 31 Dec 20 | 0 | -7 | 3 | 0 |
| 30 Sep 20 | 0 | -3 | 4 | 0 |
| 30 Jun 20 | -1 | -3 | 4 | 0 |
| 31 Mar 20 | 0 | -4 | 6 | 0 |
| 31 Dec 19 | 1 | -5 | 8 | 0 |
| 30 Sep 19 | 1 | -11 | 9 | 0 |
| 30 Jun 19 | 3 | -18 | 11 | 0 |
| 31 Mar 19 | 3 | -21 | 13 | 0 |
| 31 Dec 18 | 4 | -26 | 17 | 0 |
| 30 Sep 18 | 4 | -30 | 22 | 0 |
| 30 Jun 18 | 4 | -25 | 21 | 0 |
| 31 Mar 18 | 3 | -23 | 20 | 0 |
| 31 Dec 17 | 2 | -16 | 15 | 0 |
| 30 Sep 17 | 0 | -12 | 11 | 0 |
| 30 Jun 17 | 0 | -12 | 11 | 0 |
| 31 Mar 17 | 0 | -10 | 9 | 0 |
| 31 Dec 16 | 0 | -9 | 8 | 0 |
| 30 Sep 16 | 0 | -7 | 6 | 0 |
| 30 Jun 16 | 0 | -7 | 7 | 0 |
| 31 Mar 16 | 0 | -7 | 7 | 0 |
| 31 Dec 15 | 0 | -9 | 9 | 0 |
| 30 Sep 15 | 0 | -9 | 9 | 0 |
| 30 Jun 15 | 0 | -8 | 8 | 0 |
| 31 Mar 15 | 0 | -8 | 8 | 0 |
| 31 Dec 14 | 0 | -4 | 4 | 0 |
| 30 Sep 14 | 0 | -4 | 3 | 0 |
| 30 Jun 14 | 0 | -2 | 2 | 0 |
Quality Earnings: GBLX is currently unprofitable.
Growing Profit Margin: GBLX is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: GBLX is unprofitable, but has reduced losses over the past 5 years at a rate of 50.2% per year.
Accelerating Growth: Unable to compare GBLX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: GBLX is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-13.2%).
Return on Equity
High ROE: GBLX's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.